

RECEIVED

1644

JAN 02 2003

TECH CENTER 1600/2900

PATENTS

MAILING CERTIFICATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C.

20231 on December 27, 2002

Theodore A. Gottlieb
Theodore A. Gottlieb

PHF

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty's Docket No: 101195-64

Examiner : TBA

Group Art Unit TBA

Applicant : Stefan Anker, et al.

Appln. No. : 09/980,645

Filed : March 20, 2002

For : Therapy and Use of Compounds in Therapy

INFORMATION DISCLOSURE STATEMENT

Hon. Assistant Commissioner of Patents
Washington, D.C. 20231

Dear Sir:

The following sections are being submitted for this Information

Disclosure Statement:

- Sec. 1 - Preliminary Statements
- Sec. 2 - Identification of Time of Filing
- Sec. 4 - Statements with Respect to Listing of Information
- Sec. 6 - Statements with Respect to Copies of Listed
Information Items Accompanying This Statement

Section 1
Preliminary Statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56.

While this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56 it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(b) the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists.

Section 2
Identification of Time of Filing

This Information Disclosure Statement is filed before the issuance of the first office action.

The art was cited in the specification of the present application.

Section 4
Statements with Respect to Listing of Information

A list of the patent(s) and/or publications is set forth on the attached pages of Form PTO-1449 (modified).

Section 6
Statements with Respect to Copies of Listed Information
Items Accompanying This Statement

A copy of each of the items on PTO-1449 (modified) is supplied herewith.

Respectfully Submitted,

A handwritten signature in dark ink, appearing to read 'Theodore Gottlieb', is written over a horizontal line.

Theodore A. Gottlieb (42,597)
Attorney for Applicant
Norris, McLaughlin & Marcus P.A.
220 East 42nd Street, 30th Floor
New York, N.Y. 10017
Telephone: 212-808-0700
Facsimile: 212-808-0844



| | | | |
|--|-----------------------------------|--------------------------|---|
| U.S. PATENT AND PUBLICATIONS APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Form PTO-1449 Modified) | Attorney Docket: 101195-64 | Serial No. 09/980,645 | RECEIVED JAN 02 2003 TECH CENTER 1600/2900 |
| | Applicant: Stefan Anker et al. | | |
| | Filing Date: March 20, 2002 | Group: TBA | |

U.S. PATENT DOCUMENTS

| Examiner's Initial | | Document Number | Date | Name | Class | Sub Class | Filing Date If appropriate |
|--------------------|---|-----------------|---------|--------------------|-------|-----------|-------------------------------|
| | A | 5 1 4 9 7 9 6 | 9/22/92 | Rossi et al. | 536 | 27 | |
| | B | 5 1 4 4 0 1 9 | 9/1/92 | Rossi et al. | 536 | 27 | |
| | C | 5 1 6 8 0 5 3 | 12/1/92 | Altman et al. | 435 | 91 | |
| | D | 5 1 7 9 0 1 8 | 1/12/93 | Bogard, Jr. et al. | 530 | 388 | |
| | E | 5 8 5 8 7 2 8 | 1/12/99 | Gram et al. | | | |
| | F | 5 1 1 6 7 4 2 | 5/26/92 | Cech et al. | 435 | 91 | |
| | G | 5 0 9 3 2 4 6 | 3/3/92 | Cech et al. | 435 | 91 | |
| | H | 4 9 8 7 0 7 1 | 1/22/91 | Cech et al. | 435 | 91 | |

FOREIGN PATENT DOCUMENTS

| | | Document Number | Date | Country | Class | Sub Class | Translation Yes No |
|--|---|-----------------|------|---------|-------|-----------|-----------------------|
| | I | | | | | | |
| | J | | | | | | |
| | K | | | | | | |

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|---|---|
| L | Levine et al., "Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure", The New England Journal of Medicine - Abstract 323 (4):236, 1990 |
| M | Anker et al., "Hormonal Changes and Catabolic/Anabolic Imbalance in Chronic Heart Failure and Their Importance for Cardia Cachexia", Circulation, 96 (2):526-534, 1997 |
| N | Torre-Amione et al., "Tumor Necrosis Factor- α and Tumor Necrosis Factor Receptors in the Failing Human Heart", Circulation, 93 (4):704-711, 1996 |
| O | Anker et al., "Elevated Soluble CD14 Receptors and Altered Cytokines in Chronic Heart Failure", The American Journal of Cardiology, 79:1426-1430, 1997 |
| P | Tobias et al., "Lipopolysaccharide (LPS)-binding Proteins BPI and LBP Form Different Types of Complexes with LPS", The Journal of Biological Chemistry, 272 (30):18682-18685, 1997 |
| Q | Schumann et al., "The Lipopolysaccharide-Binding Protein Is a Secretory Class 1 Acute-Phase Protein Whose Gene Is Transcriptionally activated by APRF/STAT-3 and Other Cytokine-Inducible Nuclear Proteins", Molecular and Cellular Biology, 16 (7):3490-3503, 1996 |
| R | Lamping et al., "LPS-binding Protein Protects Mice from Septic Shock Caused by LPS or Gram-negative Bacteria", J. Clin. Invest., 101 (10):2065-2071, 1998 |
| S | Landmann et al., "Soluble CD14 Activates Monocytic Cells Independently of Lipopolysaccharide", Infection and Immunity, 66 (5):2264-2271, 1998 |
| T | Clark et al., "Exercise Limitation in Chronic Heart Failure: Central Role of the Periphery", Journal of American College of Cardiology, 28 (5):1092-1102, 1996 |
| U | Lamping et al., "Effects of Site-Directed Mutagenesis of Basic Residues (Arg 94, Lys 95, Lys 99) of Lipopolysaccharide (LPS)-Binding Protein on Binding and Transfer of LPS and Subsequent Immune Cell Activation", The Journal of Immunology, 157:4648-4656, 1996 |
| V | Ulevitch et al., "Receptor-Dependent Mechanisms of Cell Stimulation by Bacterial Endotoxin", Annual Reviews of Immunology, Abstract 13:437, 1995 |
| W | Vanderheyden et al., "Pro-inflammatory Cytokines and Endothelium-dependent Vasodilation in the Forearm", European Heart Journal, 19:747-752, 1998 |



LIST OF PATENTS AND PUBLICATIONS
APPLICANT'S INFORMATION
DISCLOSURE STATEMENT
(Form PTO-1449 Modified)

Attorney Docket:
101195-64

Serial No.
09/980,64

Applicant:
Stefan Anker et al.

Filing Date:
March 20, 2002

Group:
TBA

RECEIVED

JAN 02 2003

TECH CENTER 1600/2900

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|----|---|
| X | Vonhof et al., "Monocyte Activation in Congestive Heart failure due to Coronary Artery Disease and Idiopathic Dilated Cardiomyopathy", International Journal of Cardiology, 63:237-244, 1998 |
| Y | Randow et al., "Mechanism of Endotoxin Desensitization: Involvement of Interleukin 10 and Transforming Growth Factor Beta", Journal of Experimental Medicine, Abstract, 181:1887, 1995 |
| Z | Wilckens, "Glucocorticoids and Immune Function: Physiological Relevance and Pathogenic Potential of Hormonal Dysfunction", Viewpoint, 16:193-197, 1995 |
| AA | Anker et al., "Tumor Necrosis Factor and Steroid Metabolism in Chronic Heart Failure: Possible Relation to Muscle Wasting", Journal of the American College of Cardiology, 30 (4):997-1001, 1997 |
| AB | Barnes et al., "Nuclear Factor-kB - A Pivotal Transcription Factor in Chronic Inflammatory Diseases", The New England Journal of Medicine, 336 (15):1066-1071, 1997 |
| AC | Bachetti et al., "The Dynamic Balance Between Heart Function and Immune Activation", European Heart Journal, 19:681-688, 1998 |
| AD | Torre-Amione et al., "Expression and Functional Significance of Tumor Necrosis Factor Receptors in Human Myocardium", Circulation, 92:1487-1493, 1995 |
| AE | Bristow, "Tumor Necrosis Factor- α and Cardiomyopathy", Circulation, 97:1340-1341, 1998 |
| AF | Munger et al., "Circulating Concentrations of Proinflammatory Cytokines in Mild or Moderate Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy", Am J. Cardiol., 77:723-727, 1996 |
| AG | Keith et al., "Increased Oxidative Stress in Patients with Congestive Heart Failure", Journal of American College of Cardiology, 31 (6):1352-1356, 1998 |
| AH | Anker et al., "Tumor Necrosis Factor Alpha as a Predictor of Impaired Peak Leg Blood Flow in Patients with Chronic Heart Failure", Q. J. Med., 91:199-203, 1998 |
| AI | Tracey et al., "Metabolic Effects of Cachectin/Tumor Necrosis Factor Are Modified by Site of Production", J. Clin. Invest., 86:2014-2024, 1990 |
| AJ | Poehlman et al., "Increased Resting Metabolic Rate in Patients with Congestive Heart Failure", Annals of Internal Medicine, 121:860-862, 1994 |
| AK | Anand et al., "Studies of Body Water and Sodium, Renal Function, Hemodynamic Indexes, and Plasma Hormones in Untreated Congestive Cardiac Failure", Circulation 80:299-305, 1989 |
| AL | Dandona et al., "Procalcitonin Increase After Endotoxin Injection in Normal Subjects", J. Clin. Endocrinol Metab., 79:1605-1608, 1994 |
| AM | Sautner et al., "Early Effects of Catecholamine Therapy on Mucosal Integrity, Intestinal Blood Flow, and Oxygen Metabolism in Porcine Endotoxin Shock", Annals of Surgery, 228:239-248, 1998 |
| AN | Keel et al., "Endotoxin Tolerance After Severe Injury and its Regulatory Mechanisms", The Journal of Trauma, Injury, Infection, and Critical Care, 41:430-438, 1996 |
| AO | Yasuda et al., "Endothelin-1 Ameliorates Contractile Depression by Lipopolysaccharide in Cardiac Myocytes", A. J. Physiol. 273:H1404-H1407, 1997 |

EXAMINER:

DATE CONSIDERED:

- **EXAMINER:** Initial if Reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered, include copy of this form with next communication to applicant.



U.S. DEPARTMENT OF PATENTS AND PUBLICATIONS
APPLICANT'S INFORMATION
DISCLOSURE STATEMENT
(Form PTO-1449 Modified)

Attorney Docket:

101195-64

Serial No.

09/980,645

Applicant:

Stefan Anker et al.

Filing Date:

March 20, 2002

Group:

TBA

RECEIVED

JAN 0 2 2003


TECH CENTER 1600/2900

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|----|---|
| AP | Assicot et al., "High Serum Procalcitonin Concentrations in Patients with Sepsis and Infection", The Lancet, 341:515-518, 1993 |
| AQ | Pittman et al., "The Pathogenesis of Cardiac Cachexia", The New England Journal of Medicine, 271 (8):403-409, 1964 |
| AR | Ziegler-Heitbrock et al., "CD14: Cell Surface Receptor and Differentiation Marker", Immunology Today, 14 (3):121-125, 1993 |
| AS | Gravy et al., "Suppression of the Antigenic Response of Murine Bone Marrow B Cells by Physiological Concentrations of Glucocorticoids", Immunology, 74:519-523, 1991 |
| AT | Tang et al., "Self-stabilized Antisense Oligodeoxynucleotide Phosphorothioates: Properties and Anti-HIV Activity", Nucleic Acids Research, 21 (11):2729-2735, 1993 |
| AU | Shaw et al., "Modified Deoxyoligonucleotides Stable to Exonuclease Degradation in Serum", Nucleic Acids Research, 19 (4):747-750, 1991 |
| AV | Agrawal et al., "Inhibition of Human Immunodeficiency Virus in Early Infected and Chronically infected Cells by Antisense Oligodeoxynucleotides and their Phosphorothioate Analogues", Proc. Natl. Acad. Sci., 86:7790-7794, 1989 |
| AW | Sarin et al., "Inhibition of Acquired Immunodeficiency Syndrome Virus by Oligodeoxynucleoside Methylphosphonates", Proc. Natl. Acad. Sci. 85:7448-7451, 1988 |
| AX | Goodchild et al., "Inhibition of Human Immunodeficiency Virus Replication by Antisense Oligodeoxynucleotides", Proc. Natl. Acad. Sci., 85:5507-5511, 1988 |
| AY | Miller et al., "Targeted Vectors for Gene Therapy", The FASEB Journal, 9:190-199, 1995 |
| AZ | Agrawal et al., "Oligodeoxynucleoside Phosphoramidates and Phosphorothioates as Inhibitors of Human Immunodeficiency Virus", Proc. Natl. Acad. Sci., 85:7079-7083, 1988 |
| BA | Schumann et al., "Structure and Function of Lipopolysaccharide Binding Protein", Science, 249:1429-1431, 1990 |
| BB | Culver et al., "In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors", Science, 256:1550-1552, 1992 |
| BC | Anker et al., "Metabolic, Functional, and Haemodynamic Staging for CHF?", The Lancet, 348:1530-1531, 1996 |
| BD | Anker et al., "Wasting as Independent Risk Factor for Mortality in Chronic Heart Failure", The Lancet, 349:1050-1053, 1997 |
| BE | Bischoff et al., "An Adenovirus Mutant that Replicates Selectively in p53-Deficient Human Tumor Cells", Science, 274 (5286):373-376, 1996 |
| BF | Kelly et al., "Cytokines and Cardiac Contractile Function", Circulation, 95 (4):778781, 1997 |
| BG | Gomez-Jimenez et al., "L-arginine - Nitric Oxide Pathway in Endotoxemia and Human Septic Shock", Crit. Care Med. 23 (2):253-258, 1995 |
| | |
| | |
| | |

EXAMINER:**DATE CONSIDERED:**

- **EXAMINER:** Initial if Reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered, include copy of this form with next communication to applicant.
-



| LIST OF PATENTS AND PUBLICATIONS | | Attorney Docket: | Serial No. |
|--|---|-----------------------------------|---------------|
| APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Form PTO-1449 Modified) | | 101195-64 | 09/980,645 |
| | | Applicant: Stefan Anker et al. | |
| | | Filing Date: March 20, 2002 | Group: TBA |
| RECEIVED JAN 0 2 2003 TECH CENTER 1600/2900 | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| BH | Cotten et al., "High-Efficiency Receptor-mediated Delivery of Small and Large ...", Proc. Natl. Acad. Sci. 89:6094-6098, 1990 | | |
| BI | Wagner et al., "Transferrin-polycation Conjugates as Carriers for DNA Uptake into Cells", Proc. Natl. Acad. Sci. 87:3410-3414, 1990 | | |
| BJ | Agrawal et al., "Pharmacokinetics, Biodistribution, and Stability of Oligodeoxynucleotide Phosphorothioates in Mice", Proc. Natl. Acad. Sci., 88:7595-7599, 1991 | | |
| BK | Agrawal et al., "Nucleosite-specific Excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides", Proc. Natl. Acad. Sci., 87:1401-1405, 1990 | | |
| BL | Leiter et al., "Inhibition of Influenza Virus Replication by Phosphorothioate Oligodeoxynucleotides", Proc. Natl. Acad. Sci. 87:3430-3434, 1990 | | |
| BM | Pedersen et al., "Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)", Circulation, 97:1453-1460, 1998 | | |
| BN | Shepherd et al., "Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia", J. Med., 333 (20):1301-1307, 1995 | | |
| BO | Krschning et al., "Human Toll-like Receptor 2 Confers Responsiveness to Bacterial Lipopolysaccharide", J. Exp. Med. 188 (11):2091-2097, 1998 | | |
| BP | Walton et al., "Insulin Resistance in Chronic Heart Failure", European Heart Journal, 15:1528-1532, 1994 | | |
| BQ | Munger et al., "Arterial Oxygen Saturation in Chronic Congestive Heart Failure", Am. J. Cardiol. 73:180-185, 1994 | | |
| BR | Swedberg et al., "Hormones Regulating Cardiovascular Function in Patients with Severe Congestive Heart Failure and Their Relation to Mortality", Circulation, 82:1730-1736, 1990 | | |
| BS | Francis et al., "Plasma Norepinephrine, Plasma Renin Activity, and Congestive Heart Failure", Circulation, 87:VI-40-VI-48, 1993 | | |
| BT | Dutka et al., "Tumour Necrosis Factor α in Severe Congestive Cardiac Failure", Br. Heart J. 70:141-143, 1993 | | |
| BU | McMurray et al., "Increased Concentrations of Tumour Necrosis Factor in "Cachectic" Patients with Severe Chronic Heart Failure", Br. Heart J. 66:356-358, 1991 | | |
| BV | Michael et al., "Addition of a Short Peptide Ligand to the Adenovirus Fiber Protein", Gene Therapy, 2:660-668, 1995 | | |
| BW | Wagner et al., "Adenosine Inhibits Lipopolysaccharide-Induced Secretion of Tumor Necrosis Factor- α in the Failing Heart", Circulation, 97: 521-524, 1998 | | |
| | | | |
| | | | |
| | | | |
| EXAMINER: | | DATE CONSIDERED: | |
| <ul style="list-style-type: none">• EXAMINER: Initial if Reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered, include copy of this form with next communication to applicant.• | | | |



UNITED STATES DEPARTMENT OF PATENTS AND PUBLICATIONS
APPLICANT'S INFORMATION
DISCLOSURE STATEMENT
(Form PTO-1449 Modified)

Attorney Docket:
101195-64

Serial No.
09/980,645

Applicant:
Stefan Anker et al.

Filing Date:
March 20, 2002

Group:
TBA

RECEIVED

JAN 02 2003

TECH CENTER 1600/29

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|----|---|
| BH | Cotten et al., "High-Efficiency Receptor-mediated Delivery of Small and Large ...", Proc. Natl. Acad. Sci. 89:6094-6098, 1990 |
| BI | Wagner et al., "Transferrin-polycation Conjugates as Carriers for DNA Uptake into Cells", Proc. Natl. Acad. Sci. 87:3410-3414, 1990 |
| BJ | Agrawal et al., "Pharmacokinetics, Biodistribution, and Stability of Oligodeoxynucleotide Phosphorothioates in Mice", Proc. Natl. Acad. Sci., 88:7595-7599, 1991 |
| BK | Agrawal et al., "Nucleosite-specific Excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides", Proc. Natl. Acad. Sci., 87:1401-1405, 1990 |
| BL | Leiter et al., "Inhibition of Influenza Virus Replication by Phosphorothioate Oligodeoxynucleotides", Proc. Natl. Acad. Sci. 87:3430-3434, 1990 |
| BM | Pedersen et al., "Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)", Circulation, 97:1453-1460, 1998 |
| BN | Shepherd et al., "Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia", J. Med., 333 (20):1301-1307, 1995 |
| BO | Krschning et al., "Human Toll-like Receptor 2 Confers Responsiveness to Bacterial Lipopolysaccharide", J. Exp. Med. 188 (11):2091-2097, 1998 |
| BP | Wakon et al., "Insulin Resistance in Chronic Heart Failure", European Heart Journal, 15:1528-1532, 1994 <i>Swann et al.</i> |
| BQ | Munger et al., "Arterial Oxygen Saturation in Chronic Congestive Heart Failure", Am. J. Cardiol. 73:180-185, 1994 |
| BR | Swedberg et al., "Hormones Regulating Cardiovascular Function in Patients with Severe Congestive Heart Failure and Their Relation to Mortality", Circulation, 82:1730-1736, 1990 |
| BS | Francis et al., "Plasma Norepinephrine, Plasma Renin Activity, and Congestive Heart Failure", Circulation, 87:VI-40-VI-48, 1993 |
| BT | Dutka et al., "Tumour Necrosis Factor α in Severe Congestive Cardiac Failure", Br. Heart J. 70:141-143, 1993 |
| BU | McMurray et al., "Increased Concentrations of Tumour Necrosis Factor in "Cachectic" Patients with Severe Chronic Heart Failure", Br. Heart J. 66:356-358, 1991 |
| BV | Michael et al., "Addition of a Short Peptide Ligand to the Adenovirus Fiber Protein", Gene Therapy, 2:660-668, 1995 |
| | |
| | |
| | |
| | |
| | |

EXAMINER:

DATE CONSIDERED:

- **EXAMINER:** Initial if Reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformation and not considered, include copy of this form with next communication to applicant.
-